Oncology
OncoX and ABVC BioPharma Strengthen Collaboration to Advance Oncology Treatments
OncoX BioPharma's deepened alliance with ABVC BioPharma signifies a strategic move to enhance its oncology pipeline, leveraging ABVC's IND-stage programs to develop innovative cancer therapies.
Lantern Pharma Achieves Milestone in Phase 2 HARMONIC Trial for Non-Smoker NSCLC Patients in Japan
Lantern Pharma completes targeted enrollment for its Phase 2 HARMONIC trial in Japan, marking a significant step in its international expansion and offering hope for never-smoker NSCLC patients.
Calidi Biotherapeutics Inc. Receives FDA Fast Track Designation for CLD-201 in Soft Tissue Sarcoma
Calidi Biotherapeutics Inc. has been granted FDA Fast Track designation for its CLD-201 treatment, marking a significant step forward in the development of therapies for soft tissue sarcoma and other cancers.
Lantern Pharma Strengthens Board with Appointment of Dr. Lee T. Schalop to Advance AI-Driven Oncology Research
Lantern Pharma enhances its AI-driven precision oncology efforts by appointing Dr. Lee T. Schalop, a seasoned biotech leader, to its Board of Directors.
Soligenix Inc. Advances in Oral Mucositis Treatment with SGX942
Soligenix Inc. is making strides with SGX942, a novel treatment for severe oral mucositis, showing promise in reducing the condition's severity and duration in cancer patients.
Candel Therapeutics' CAN-2409 Receives European Orphan Designation for Pancreatic Cancer Treatment
The European Medicines Agency grants Orphan Designation to Candel Therapeutics' CAN-2409, highlighting its potential to address the significant unmet medical need in pancreatic cancer treatment across Europe.
ABVC BioPharma Receives $100,000 Milestone Payment from OncoX BioPharma, Strengthening Oncology Partnership
ABVC BioPharma's latest milestone payment from OncoX BioPharma underscores the growing commercial value of their oncology platform and the potential for global market expansion in botanical-based cancer treatments.
GeoVax Shifts Gedeptin® Strategy to Neoadjuvant Combination Trial After KEYNOTE-689 Success
GeoVax Labs, Inc. announces a strategic pivot in its Gedeptin® clinical development program towards a neoadjuvant therapy combination with pembrolizumab for head and neck squamous cell carcinoma, following promising KEYNOTE-689 Phase 3 trial results.
Akari Therapeutics CEO Unveils Novel ADC Platform Targeting Cancer Resistance
Akari Therapeutics, under CEO Abizer Gaslightwala, is pioneering a novel ADC platform aimed at overcoming cancer resistance and enhancing treatment durability through immune system activation.
Lantern Pharma Reports First Complete Response in Phase 1 LP-284 Trial for Aggressive DLBCL
Lantern Pharma's LP-284 shows promising results in a Phase 1 trial for aggressive DLBCL, marking a significant step forward in the treatment of refractory lymphomas.
CNS Pharmaceuticals Inc. CEO Highlights Company's Vision at Virtual Investor Conference
CNS Pharmaceuticals Inc. CEO John Climaco's participation in the Virtual Investor Summer Spotlight Conference underscores the company's commitment to developing innovative treatments for brain and central nervous system cancers.
Calidi Biotherapeutics Inc. to Showcase RedTail Platform and Oncology Advancements in Investor Webinar
Calidi Biotherapeutics Inc. (NYSE American: CLDI) will host an investor webinar to discuss its RedTail platform and advancements in oncology, highlighting the potential of its CLD-401 candidate to eliminate tumors and activate immune memory.
CLL Society Honors Innovators in Leukemia and Lymphoma Research
The CLL Society has awarded three researchers for their innovative projects aimed at improving care and outcomes for patients with chronic lymphocytic leukemia and small lymphocytic lymphoma, highlighting the importance of integrative medicine, clinical research, and overcoming treatment resistance.
Lantern Pharma Secures EU Patent for AI-Designed Cancer Drug LP-284
Lantern Pharma's EU patent for LP-284, an AI-designed cancer drug, marks a significant step in global commercialization and treatment for non-Hodgkin’s lymphoma.
Soligenix Inc. Reports Promising Results in HyBryte(TM) Trial for Early-Stage Cutaneous T-Cell Lymphoma
Soligenix Inc.'s HyBryte(TM) shows promising treatment success in early-stage cutaneous T-cell lymphoma, offering hope for patients with limited options.
Lantern Pharma Unveils AI Module to Enhance Cancer Combination Therapies Development
Lantern Pharma introduces an AI-powered module to streamline the creation of targeted cancer combination therapies, promising to cut development time and costs significantly.
Lantern Pharma Engages IBN for Corporate Communications Strategy Amid AI-Driven Oncology Pipeline Advancements
Lantern Pharma partners with IBN to enhance investor awareness as it progresses its AI-driven oncology pipeline, including therapies for lung, brain, breast, and blood cancers.
Kairos Pharma Ltd. to Showcase Oncology Innovations at H.C. Wainwright Global Investment Conference
Kairos Pharma Ltd. (NYSE American: KAPA) will present its advancements in cancer therapeutics at the H.C. Wainwright 27th Annual Global Investment Conference, highlighting its potential to address drug resistance in cancer treatments.
Kairos Pharma Ltd. Reports Positive Safety Results in Phase 2 Study of Prostate Cancer Drug ENV-105
Kairos Pharma Ltd. announces favorable interim safety results from its Phase 2 trial of ENV-105 for metastatic castration-resistant prostate cancer, marking a significant step forward in cancer therapy.
UC Davis Study Uncovers Genetic Mutation Affecting Immunotherapy Response in Solid Tumors
A study by UC Davis scientists reveals a genetic mutation that may explain why solid tumors are unresponsive to immunotherapy, potentially leading to more effective cancer treatments.
Lantern Pharma Inc. Harnesses AI to Revolutionize Oncology Drug Development
Lantern Pharma Inc. (NASDAQ: LTRN) is utilizing its AI-driven RADR(R) platform to accelerate the development of precision cancer therapies, marking a significant advancement in oncology drug discovery.
University of Plymouth Researchers Identify Proteins Linked to Brain Tumor Growth
Researchers at the University of Plymouth have discovered proteins crucial for the growth of common brain tumors, paving the way for less invasive treatments.
Calidi Biotherapeutics Inc. Advances Oncology Pipeline and Strategic Goals in 2025
Calidi Biotherapeutics Inc. outlines significant progress in its oncology immunotherapy pipeline and strategic initiatives aimed at enhancing shareholder value and advancing cancer treatment options.
Lantern Pharma's AI Platform Shows Promise in Lung Cancer Treatment
Lantern Pharma's AI-driven drug development platform, RADR®, has demonstrated significant potential in treating non-small cell lung cancer, with a Phase 2 trial patient achieving a complete response after previous treatments failed.
New Scanning Method Research Funded to Improve Brain Tumor Treatment
Researchers from NHS Grampian and the University of Aberdeen receive funding to explore a novel scanning method that could enhance the treatment of aggressive brain tumors, specifically glioblastomas.
CNS Pharmaceuticals Inc. Sheds Light on GBM Treatment Advances in KOL Segment
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) explores the potential of its lead product candidate, TPI 287, in treating Glioblastoma Multiforme (GBM) and future metastatic tumor indications, as discussed by Dr. Erin Dunbar in a recent Virtual Investor KOL Connect segment.
FDA Approval of Keytruda® in Head and Neck Cancer Highlights Potential for Gedeptin® Combination Therapy
The FDA's approval of Keytruda® for head and neck cancer treatment underscores the therapeutic potential of combining it with GeoVax’s Gedeptin®, aiming to enhance tumor clearance and reduce relapse rates.
Lantern Pharma Inc. Reports Complete Response in Advanced NSCLC Patient in HARMONIC(TM) Trial
Lantern Pharma Inc. (NASDAQ: LTRN) has reported a significant clinical outcome in its Phase 2 HARMONIC(TM) trial, showcasing the potential of its LP-300 treatment in combination with standard chemotherapy for never-smoker patients with advanced non-small cell lung cancer (NSCLC), marking a pivotal moment in oncology treatment.
Electric Fields Found to Enhance Immune Response Against Glioblastoma
A recent study by the University of Southern California reveals that electric fields can significantly boost the immune system's fight against glioblastoma, offering hope for extended patient survival and new treatment avenues.
Lantern Pharma Advances Precision Oncology with AI-Driven Platform
Lantern Pharma Inc. leverages its AI-driven RADR(R) platform to accelerate the development of precision cancer therapies, with three lead drug candidates in clinical trials and multiple FDA designations enhancing its regulatory pathways.